BVS (Bioventus) Total Receivables: $120.5 Mil (As of Mar. 2026)


BVS Bioventus Inc BVS
69 GF Score
Price $9.85
GF Value $6.80
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Bioventus Total Receivables?

Bioventus BVS +4.29% 69 Total Receivables is $120.5 Mil as of Mar. 2026. GuruFocus rates BVS with a GF Score™ of 69/100 and a GF Value™ of $6.80 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Bioventus's Total Receivables for the quarter that ended in Mar. 2026 was $120.5 Mil.

Bioventus Total Receivables Historical Data

* Premium members only.

The historical data trend for Bioventus's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventus Total Receivables Chart

Bioventus Annual Data
Trend Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.96 136.30 122.79 127.39 128.30

Bioventus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.08 132.37 130.40 128.30 120.53
BVS
69GF Score
Bioventus Inc BVS
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioventus Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $120.5 Mil mean?
Bioventus (BVS) has a Total Receivables of $120.5 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bioventus and its competitors.
Is Bioventus' Total Receivables too high?
Bioventus' current Total Receivables is $120.5 Mil. Overall, Bioventus has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' Total Receivables compare to SSII and TCMD?
Bioventus' Total Receivables of $120.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bioventus and its competitors. Bioventus's current Total Receivables is $120.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (BVS) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.80, compared to a current price of $9.85 — trading 44.9% above its estimated fair value. The current Total Receivables is $120.5 Mil. Bioventus' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bioventus (BVS), the current Total Receivables is $120.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioventus (BVS) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventus stock appears to be overvalued. The current stock price of $9.85 is trading 44.9% above its estimated GF Value™ of $6.80. GuruFocus considers Bioventus to be Significantly Overvalued.

Key valuation signals for BVS:

  • Total Receivables: $120.5 Mil
  • GF Value™: $6.80 vs. price of $9.85 (44.9% above fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventus Business Description

Other Exchanges 4B8:Germany
Address 4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
69GF Score

Get the complete analysis for BVS

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.85
Price
$6.80
GF Value